Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute- Waldenström Macroglobulinemia 1

Leukemia and Lymphoma

Volumn 54, Issue 2, 2013, Pages 387-396

  Chitta, Kasyapa S ^a,b   Paulus, Aneel ^c   Ailawadhi, Sikander ^b   Foster, Barbara A ^d   Moser, Michael T ^d   Starostik, Petr ^d   Masood, Aisha ^d   Sher, Taimur ^a   Miller, Kena C ^a,c   Iancu, Dan M ^d   Conroy, Jeffrey ^e   Nowak, Norma J ^e,f   Sait, Sheila N ^d   Personett, David A ^b   Coleman, Morton ^g   Furman, Richard R ^g   Martin, Peter ^g   Ansell, Stephen M ^h   Lee, Kelvin ^a,c   Chanan Khan, Asher A ^a,b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Tisch Cancer Institute   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h MAYO CLINIC   (United States)

Author keywords

Cell line; Model; Preclinical; Waldenstr m macroglobulinemia

Indexed keywords

BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CELL SURFACE MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M; LENALIDOMIDE; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN BCL 2; RITUXIMAB; SILDENAFIL; THALIDOMIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CASE REPORT; CHROMOSOME DELETION; CHROMOSOME DELETION 18Q21; CHROMOSOME DELETION 6Q21; CHROMOSOME DELETION 9P21; CHROMOSOME NUMBER; DISEASE COURSE; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LYMPHADENOPATHY; MONOCLONAL IMMUNOGLOBULINEMIA; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENOMEGALY; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CYTOGENETIC ANALYSIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN M; IMMUNOPHENOTYPING; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ALIGNMENT; TRANSPLANTATION, HETEROLOGOUS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84872038376     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.713481     Document Type: Article

References (32)

1. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007; 109: 5096-5103.
2. Stone MJ, Pascual V. Pathophysiology of Waldenstrom'smacroglobulinemia. Haematologica 2010; 95: 359-364.
3. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom'smacroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom'sMacroglobulinemia. Semin Oncol 2003; 30: 110-115.
4. Walsh SH, Laurell A, Sundstrom G, et al. Lymphoplasmacytic lymphoma/Waldenstrom'smacroglobulinemia derives from an extensively hypermutated Bcell that lacks ongoing somatic hypermutation. Leuk Res 2005; 29: 729-734.
5. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom'smacroglobulinemia. JClin Oncol 2005; 23: 1564-1577.
6. Kriangkum J, Taylor BJ, Treon SP, et al. Molecular characterization of Waldenstrom'smacroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin Cancer Res 2007; 13: 2005-2013.
7. Xu L, Sohani A, Arcaini L, et al. Asomatic variant in MYD88 (L265P) revealed by whole genome sequencing differentiates lymphoplasmacytic lymphoma from marginal zone lymphomas. Blood 2011; 118(Suppl. 1): Abstract 261.
8. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
9. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in Waldenstrom'smacroglobulinemia: an update of aUS intergroup trial (SW0G S9003). Semin Oncol 2003; 30: 220-225.
10. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom'smacroglobulinemia. Clin Lymphoma 2005; 5: 273-277.
11. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom'smacroglobulinemia. Clin Lymphoma Myeloma 2009; 9: 62-66.
12. Treon SP. How Itreat Waldenstrom macroglobulinemia. Blood 2009; 114: 2375-2385.
13. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009; 113: 3673-3678.
14. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004; 45: 2047-2055.
15. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. JClin Oncol 2009; 27: 3830-3835.
16. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom'sMacroglobulinemia. JClin Oncol 2009; 27: 120-126.
17. Varghese AM, Rawstron AC, Ashcroft AJ, et al. Assessment of bone marrow response in Waldenstrom'smacroglobulinemia. Clin Lymphoma Myeloma 2009; 9: 53-55.
18. Barakat FH, Medeiros LJ, Wei EX, et al. Residual monotypic plasma cells in patients with Waldenstrom macroglobulinemia after therapy. Am JClin Pathol 2011; 135: 365-373.
19. Drexler HG. Guide to leukemia-lymphoma cell lines. Braunschweig: DSMZ; 2010.
20. Muirhead KA, Wallace PK, Schmitt TC, et al. Methodological considerations for implementation of lymphocyte subset analysis in aclinical reference laboratory. Ann NY Acad Sci 1986; 468: 113-127.
21. Matsui S, Faitar SL, Rossi MR, et al. Application of spectral karyotyping to the analysis of the human chromosome complement of interspecies somatic cell hybrids. Cancer Genet Cytogenet 2 003; 1 42: 3 0-3 5.
22. Ried T, Koehler M, Padilla-Nash H, et al. Chromosome analysis by spectral karyotyping. In: Spector DL, Goldman RD, Leinwand LA, editors. Cells: alaboratory manual. New York: CSHL Press; 1997.
23. Tang K, Fu DJ, Julien D, et al. Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci USA 1999; 96: 10016-10020.
24. UCSC Genome Bioinformatics [Internet]. 2012. Available from: http://genome.ucsc.edu/index.html
25. Schop RF, Van Wier SA, Xu R, et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006; 169: 150-153.
26. Berger F, Isaacson PG, Piris MA, et al. Lymphoplasmacytic lymphoma/Waldenstr ö mmacroglobulinemia. In: JaffeES, Harris NL, Stein H, et al., editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 132-134.
27. Quesnel B, Preudhomme C, Fenaux P. p16ink4a gene and hematological malignancies. Leuk Lymphoma 1996; 22: 11-24.
28. Bergh G, Ehinger M, Olofsson T, et al. Altered expression of the retinoblastoma tumor-suppressor gene in leukemic cell lines inhibits induction of differentiation but not G1-accumulation. Blood 1997; 89: 2938-2950.
29. Tam W, Gomez M, Chadburn A, et al. Mutational analysis of PRDM1 indicates atumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107: 4090-4100.
30. Ray ME, Wistow G, Su YA, et al. AIM1, anovel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. Proc Natl Acad Sci USA 1997; 94: 3229-3234.
31. Iqbal J, Kucuk C, Deleeuw RJ, et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009; 23: 1139-1151.
32. Drexler HG, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of Waldenstrom'smacroglobulinemia. Leuk Res 2008; 32: 1669-1673.